Trying to fight depression might seem impossible, but this is not true if you put in the work. There are many ways to deal with the fatigue and emptiness that you suffer with, and there are also several tricks to help you go on with life even while suffering from depression. I’ve discussed them all below. Read ahead.
The lethargy that depression plagues you with makes life difficult; you would feel too drained to do any of the work that you have to do. However, life must go on. Creating smaller goals for whatever you need to do might help.
For example, if you have to clean the house, start by first taking the trash out. And if you need to do the laundry, don’t do all the clothes that have piled up but just do a certain color of clothes first.
Once you’re done with a small goal, set your eyes on another. Moving from one small task to another will feel less draining than attempting a giant To-Do list.
Reward yourself for not letting your depression stop you from doing what you need to do. This would be a tactic to help keep you from falling into a slump. Now, it’s up to you to decide what you want to reward yourself with.
Spend Time Outdoors
Several studies have shown that regularly going outdoors helps patients that are suffering from depression. Why? Because sunlight increases serotonin levels. Low serotonin levels are responsible for depression.
Being one with nature can also help you feel better, as you’ll realize how grand life is. Your problems might start to feel small.
Watch What You Eat
Although you might not think it, what you eat plays a major role in how you feel. Consuming a lot of sugary, processed, and preserved foods negatively affects your mental health in the long run.
Many patients suffering from depression have said that filling their diets up with natural foods have boosted their mental health expotentinally.
Try Medical Marijuana
Medical marijuana has a high percentage of cannabidiols. Also known as CBDs, they are compounds that have soothing effects. What makes medical marijuana different from regular marijuana is the fact that there is no THC in it. THC is the compound responsible for the euphoric feeling that recreational cannabis provides. However, it can induce a sense of doom and paranoia too.
When looking for a weed store in Kingston, do your research. You want to buy from a dispensary that sells medical marijuana buds with as high of a percentage of cannabidiols as possible.
Big names like Leafy Things, Weed Products and Services should be your go-to.
Although it might feel impossible for you to exercise while being void of energy, working out will be beneficial. Exercise releases endorphins that are known as “feel-good” hormones. Your mood would improve, as a result.
Improving your physique and not sitting in bed all day will help you feel better as well.
Depression can make your life difficult due to the emptiness and fatigue you feel. However, there are many points that will help. One of the best would be to create smaller goals for whatever you need to do. Also, trying medical marijuana might help for the days that are extra down too.
Merck’s COVID-19 pill significantly less effective in new analysis
Merck & Co said on Friday updated data from its study of its experimental COVID-19 pill showed the drug was significantly less effective in cutting hospitalizations and deaths than previously reported.
The drugmaker said its pill showed a 30% reduction in hospitalizations and deaths, based on data from 1,433 patients. In October, its data nL1N2QX0QJ showed a roughly 50% efficacy, based on data from 775 patients. The drug, molnupiravir, was developed with partner Ridgeback Biotherapeutics.
The lower efficacy of Merck’s drug could have big implications in terms of whether countries continue to buy the pill. Interim data from 1,200 participants in Pfizer Inc’s trial for its experimental pill, Paxlovid, showed an 89% reduction in hopsitalizations and deaths.
Merck’s shares fell 3.5% to $79.39 in morning trading.
Merck released the data before the U.S Food and Drug Administration published a set of documents on Friday intended to brief a panel of outside experts who will meet on Tuesday to discuss whether to recommend authorizing the pill.
The agency’s staff did not make their own recommendation as to whether the pill should be authorized.
FDA staff asked the panel to discuss whether the benefits of the drug outweigh the risks and whether the population for whom the drug should be authorized should be limited.
They also asked the committee to weigh in on concerns over whether the drug could encourage the virus to mutate, and how those concerns could be mitigated.
Pills like molnupiravir and Paxlovid could be promising new weapons in the fight against the pandemic, as they can be taken as early at-home treatments to help prevent COVID-19 hospitalizations and deaths. They could also become important tools in countries and areas with limited access to vaccines or low inoculation rates.
The Merck and Pfizer pills are cheaper to produce and easier to administer than existing treatment options such as antibody therapies from Regeneron and Eli Lilly, which are mostly administered as intravenous infusions.
The two experimental drugs have different mechanisms of action. Merck’s is designed to introduce errors into the genetic code of the virus. Pfizer’s drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.
Merck filed for a U.S. authorization of molnupiravir on Oct. 11, following the interim data, and submitted the updated data to the FDA this week.
The molnupiravir arm of the study had a hospitalization and death rate of 6.8%, according to the updated data. The placebo group had a hospitalization and death rate of 9.7%.
One patient in the molnupiravir arm died, versus nine in the placebo group.
The United Kingdom conditionally approved molnupiravir, branded as Lagevrio, earlier this month.
Merck expects to produce 10 million courses of the treatment by the end of this year, with at least 20 million set to be manufactured in 2022. It has a contract with the U.S. government to supply as many as 5 million courses at a price of $700 per course. Several other countries have already secured millions of courses of the pill.
Merck has said data shows molnupiravir is not capable of inducing genetic changes in human cells, but men enrolled in its trials had to abstain from heterosexual intercourse or agree to use contraception. Women of child-bearing age also had to use birth control.
Still, the FDA said in its briefing document that there are safety concerns about potential birth defects from the drug and asked the panel to discuss whether the drug should be available to pregnant women.
(Reporting by Manas Mishra in Bengaluru and Michael Erman in New JerseyEditing by Shounak Dasgupta, Frances Kerry and Emelia Sithole-Matarise)
Brazil health regulator calls for Africa travel restrictions, Bolsonaro noncommittal
Brazilian health regulator Anvisa recommended on Friday that travel be restricted from some African countries due to the detection of a new COVID-19 variant, though it was unclear if President Jair Bolsonaro would adopt any measures.
Anvisa said its recommendation, which would need government approval to be implemented, was to immediately suspend flights from South Africa, Botswana, Lesotho, Eswatini, Namibia and Zimbabwe.
The EU and Britain are already tightening border controls as researchers look into whether the new mutation is vaccine-resistant.
Brazil’s Health Ministry said in a separate note that the new B.1.1.529 variant named Omicron poses a potential future threat, but that its epidemiological impact was unclear.
After the Anvisa statement, Bolsonaro told journalists he was considering taking measures related to the variant but continued to emphasize that he was against severe coronavirus-related restrictions.
“Brazil can’t handle another lockdown. There’s no use getting terrified,” he said after a military event in Rio de Janeiro. “I’m going to take rational measures.”
Bolsonaro has been widely criticized by public health experts for his management of the pandemic, railing against lockdowns, often refusing to wear a mask in public and choosing not to get vaccinated. Brazil has the world’s second-highest death toll from the virus, behind only the United States.
The World Health Organization (WHO) has cautioned countries against hastily imposing travel restrictions due to the variant, saying they should take a “risk-based and scientific approach.”
In its technical note, Anvisa said that foreigners who have been to at least one of the six African countries cited in the prior 14 days should not be allowed to land in Brazil, while Brazilians arriving from those nations should be required to quarantine.
The health agency said, “The new variant appears to have a higher transmissibility.”
Anvisa President Antonio Barra Torres told news channel GloboNews that travel restrictions are a necessary preventive measure and he expected the government to make a decision as soon as possible.
The news of the variant hammered travel stocks in Brazil.
(Reporting by Gabriel Araujo in Sao Paulo and Lisandra Paraguassu in BrasiliaAdditional reporting by Rodrigo Viga Gaier in Rio de Janeiro and Eduardo Simoes in Sao PauloWriting by Stephen Eisenhammer and Gram SlatteryEditing by Brad Haynes and Alistair Bell)
Novavax developing vaccine that targets new COVID-19 variant
Novavax Inc said on Friday it had started working on a version of its COVID-19 vaccine to target the variant detected in South Africa and would have the shot ready for testing and manufacturing in the next few weeks.
The company’s COVID-19 shot contains an actual version of the virus’ spike protein that cannot cause disease but can trigger the immune system. The vaccine developer said it had started developing a spike protein specifically based on the known genetic sequence of the variant, B.1.1.529.
“The initial work will take a few weeks,” a company spokesperson said. Shares of the company closed up nearly 9% on Friday.
Novavax’s vaccine received its first emergency use approval earlier this month in Indonesia followed by the Philippines.
The company has said it is on track to file for U.S. approval by the end of the year. It has also filed for approvals with the European Medicines Agency as well as in Canada.
Other vaccine developers, including Germany’s BioNTech SE and Johnson & Johnson, have said they are testing the effectiveness of their shots against the new variant, which is named Omicron by the World Health Organisation.
Inovio Pharmaceuticals Inc said it had begun testing its vaccine candidate, INO-4800, to evaluate its effectiveness against the new variant. The company expects the testing to take about two weeks.
Inovio also said it was simultaneously designing a new vaccine candidate that specifically targeted Omicron.
“Best case scenario, INO-4800 … will be completely resilient against omicron, but if that’s not the case then we will have a newly designed vaccine ready to go if need be,” said Kate Broderick, senior vice president of Inovio’s R&D division.
Earlier this month, Inovio resumed a late-stage trial of its vaccine in the United States after 14 months on clinical hold.
(Reporting by Manojna Maddipatla and Mrinalika Roy in Bengaluru; Editing by Anil D’Silva)
What's Happening in the World Economy: Virus Fears Return – Bloomberg
Ocean Economy: The Next Wave of Sustainable Innovation – Visual Capitalist
Stores kick off Black Friday but pandemic woes linger – CP24 Toronto's Breaking News
Silver investment demand jumped 12% in 2019
Europe kicks off vaccination programs | All media content | DW | 27.12.2020 – Deutsche Welle
Iran anticipates renewed protests amid social media shutdown
News4 hours ago
Broadway legend Stephen Sondheim dead at 91
News10 hours ago
Coronavirus: Femicide rate on rise, Canadian researcher says – CTV News
News4 hours ago
Tunisian police say they shot, wounded extremist trying to attack them
Media4 hours ago
Does your social media profile belong in your will? Why Canadians should plan their ‘digital inheritance’ now – Globalnews.ca
News24 hours ago
Coronavirus: What's happening in Canada and around the world on Thursday – CBC.ca
Sports21 hours ago
Jacobs rink in good shape heading into last day of round robin at curling trials – SooToday
Art17 hours ago
Art Beat: Inspirato shares its pandemic journey in weekend concerts – Coast Reporter
Health4 hours ago
Brazil health regulator calls for Africa travel restrictions, Bolsonaro noncommittal